Testing a stroke drug to improve recovery after ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether sovateltide is safe and can improve recovery in people with an acute ischemic stroke. It focuses on patients who start the study drug within 24 hours of symptom onset and do not have bleeding in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 78 years old (not yet 79).
- Your stroke is ischemic (caused by blocked blood flow) and brain scans (CT or MRI) show no bleeding.
- You are enrolled within 24 hours of when symptoms started (or when you were last known well for wake-up strokes).
- Your stroke severity is moderate: mRS 3–4 before this new stroke had you been 0–1, and NIHSS is over 5 (with a specific alertness score under 2).
- You can commit to getting the full treatment course and coming back for follow-up visits.
- You (or a legally authorized representative) can give informed consent before any study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies sovateltide (and a placebo) in adults with an ischemic stroke, aiming to improve safety and outcomes. It focuses on people who can start treatment quickly after stroke symptoms begin and who do not have bleeding in the brain on imaging.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.
This trial tests a new treatment called NouvSoma001 for people who have had an ischemic stroke within the last week. It aims to see if the treatment is safe and helps improve muscle strength and overall recovery.
Hear when a new Acute Cerebral Ischemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.